Electro-Optical completes MelaFind trial
This article was originally published in Clinica
Electro-Optical Sciences (EOS), of Irvington, New York, has completed its pivotal trial of MelaFind, its melanoma detection device. MelaFind was used to evaluate over 1,800 suspicious skin lesions from over 1,300 patients. All the lesions deemed "suspicious" by the system were subsequently biopsied and sent for dermatohistopathologic analysis. Results are anticipated in the fourth quarter of 2008, with a PMA application to the US FDA to follow. The noninvasive, hand-held imaging system emits multiple wavelengths of light to obtain data on suspicious pigmented skin lesions up to 2.5mm deep. It analyses these data using proprietary algorithms to compare them with a database of melanomas and benign lesions.